<DOC>
	<DOCNO>NCT02632747</DOCNO>
	<brief_summary>This randomize , double-blind , double-dummy , placebo-controlled , cross design trial empagliflozin compare placebo add open-label ramipril patient type 1 diabetes .</brief_summary>
	<brief_title>Empagliflozin ACEi Effects Hyperfiltration Type 1 Diabetes ( BETWEEN Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Signed date write informed consent . Male female patient diagnose type 1 diabetes least 6 month prior inform consent . Use willing continue throughout duration trial either : multiple daily injection insulin OR continuous subcutaneous insulin infusion insulin type , least 3 month experience HbA1c 6.5 11 % Age least 18 year age Body mass index 18.5 35 kg/m2 Estimated glomerular filtration rate great equal 60 ml/min/1.73m2 Blood pressure great 90 /60 mmHg less equal 140 / 90 mmHg Use highly effective method contraception . Further inclusion criterion apply Exclusion criterion : Treatment antihyperglycaemic agent within 3 month prior visit 1 occurrence severe hypoglycaemia within 3 month prior visit 1 hypoglycaemic unawareness within 3 month prior visit 1 occurrence diabetic ketoacidosis within 3 month visit 1 visit 3 Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>